[Federal Register: October 29, 2003 (Volume 68, Number 209)]
[Notices]               
[Page 61699]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr29oc03-61]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances Notice of Application

    Pursuant to section 1301.33(a) of title 21 of the Code of Federal 
Regulations (CFR), this is notice that on August 6, 2003, Guilford 
Pharmaceuticals, Inc., 6611 Tributary Street, Baltimore, Maryland 
21224, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of cocaine 
(9041) a basic class of controlled substance listed in Schedule II.
    The firm plans to manufacture a Schedule II cocaine derivative as a 
final intermediate for the production of dopascan injection.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than [December 
29, 2003].

    Dated: October 7, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 03-27240 Filed 10-28-03; 8:45 am]

BILLING CODE 4410-09-M